Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors-Reference-Cited by-同舟云学术

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

Published:2011-02-15 Issue:4 Volume:17 Page:630-635
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

GRINGERI A.,FISCHER K.,KARAFOULIDOU A.,KLAMROTH R.,LÓPEZ-FERNÁNDEZ M. F.,MANCUSO E.,

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2010.02467.x/fullpdf

Reference20 articles.

1. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review;Lloyd-Jones;Haemophilia,2003

2. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group;Gringeri;Blood,2003

3. Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors;Gringeri;Haemophilia,2005

4. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors’ Organisation;Hay;B J Haematol,2006

5. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study;Astermark;Blood,2007

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies;Medicina;2023-09-28

2. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors;Expert Review of Hematology;2023-09-25

3. Current status and future prospects of activated recombinant coagulation factor VIIa, NovoSeven®, in the treatment of haemophilia and rare bleeding disorders;Annals of Hematology;2023-06-30

4. Hematological treatment and prophylaxis in patients with and without inhibitors;Blood Coagulation & Fibrinolysis;2023-06

5. Factor VIIa/factor X製剤と高用量recombinant factor VIIa製剤の併用療法を施行した血友病Bインヒビター1症例の凝固能評価;Japanese Journal of Thrombosis and Hemostasis;2023